# TroFuse-005: what clinicians are saying > 222 statements from 72 sources (9 podcasts, 7 videos, 54 posts, 1 paper, 1 registry record), 66 of them from 22 confirmed clinicians, each linked to its source. Commentary checked Nov 12, 2026. ## Report - Trial: A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy (MK-2870-005/ENGOT-en23/GOG-3095) - NCT ID: NCT06132958 - Registry: https://clinicaltrials.gov/study/NCT06132958 - Sponsor: Merck Sharp & Dohme LLC - Phase: Phase 3 - Status: Active, not recruiting - Drugs tested: sacituzumab tirumotecan - Indication: endometrial cancer after platinum-based chemotherapy and immunotherapy - Version: v1.0.0, edition 1 - Accepted: 2026-11-12 UTC - Last checked: 2026-11-12 UTC - Release hash: eac21b48fa95ee6198488c48be4baa4b54cfb21e4611c4917bb1f6ad67d3e268 ## Counts - Commentary sources screened: 160 - Sources cited by verified statements: 72 - Verified statements: 222 - From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 66 - Findings: 6 - Named people in screened sources (unnamed speakers and accounts not counted): 37 - Speakers cited: 35 - Cited speakers with a verified identity: 26 - Cited clinicians, speakers with a confirmed clinical role (the abstract's clinicians): 22 - Of them physicians, whose confirmed role is a physician's, not a physician assistant's, nurse's or pharmacist's (the abstract's physicians): 22 - By role and specialty (the abstract's specialty counts): - 9 physician, Medical oncology - 8 physician, Surgical oncology - 3 physician, specialty not confirmed - 1 physician, Gynecologic oncology - 1 physician, Pathology - Organisational or shared accounts (not counted as people): 21 A verified identity says who a speaker is. A cited clinician also has a clinical role confirmed by the NPI registry or their own institution's staff page. Verified speakers without such a role, such as researchers, advocates, company staff, or clinicians whose role only a source or their own profile states, are not counted as clinicians. Counts describe the retained sources. They do not estimate how many HCPs hold a view. ## Abstract A speaker described in the sources as presenting TroFuse-005 endorses routine sac-TMT use today, citing survival benefit they consider clinically meaningful, but a medical oncologist wants longer-term safety evidence before wider use. That caution reflects increased severe treatment-related toxicity. Conflicting authorization accounts leave current approval and funded access unclear. ## Question clinicians left open What do clinicians say they still need to see on longer-term safety, biomarker analyses, subgroup results and treatment sequencing before broadly adopting sacituzumab tirumotecan for recurrent endometrial cancer after platinum chemotherapy and immunotherapy? From finding F1 (14 statements from 8 speakers in 9 sources). The report shows what clinicians said and the sources behind it; it does not settle the question. ## Findings (titles) - F1. One interview calls sac-TMT a current standard of care; clinical accounts qualify broad adoption - 14 statements from 8 speakers in 9 sources, 1 of them a podcast or video. - F2. Clinical accounts weigh survival gains against greater toxicity; one episode links manageability to prevention - 18 statements from 6 speakers in 13 sources, 2 of them podcasts or videos. - F3. Clinical accounts ask who should receive sac-TMT and how to sequence it with other ADCs - 9 statements from 3 speakers in 6 sources, 1 of them a podcast or video. - F4. One speaker defends the chemotherapy comparator; other accounts stress evidence maturity - 13 statements from 6 speakers in 9 sources, 2 of them podcasts or videos. - F5. Accounts distinguish clinical enthusiasm from authorization and access - 15 statements from 3 speakers in 11 sources, 4 of them podcasts or videos. - F6. Speakers explain sac-TMT through targeted-delivery analogies; one report cautions against cure expectations - 14 statements from 3 speakers in 6 sources, 5 of them podcasts or videos. The full report also has 7 findings about other patients, lines of treatment or settings, after these trial findings under “Beyond the trial population”. They are not counted or listed on this page. ## What sits behind each finding Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding. Speakers are the named people a finding's statements cite, of any role, counted as the report counts its cited speakers; unnamed speakers and accounts are not counted. | Finding | Statements | Passages | Sources | Speakers | Limitations | | --- | ---: | ---: | ---: | ---: | ---: | | F1 | 14 | 9 | 9 | 8 | 2 | | F2 | 18 | 21 | 13 | 6 | 2 | | F3 | 9 | 7 | 6 | 3 | 3 | | F4 | 13 | 11 | 9 | 6 | 3 | | F5 | 15 | 12 | 11 | 3 | 3 | | F6 | 14 | 12 | 6 | 3 | 3 | ### What the statements are | Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Statement links to supporting passages | Statement links to context passages | Sources by kind | | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | | F1 | 10 | 1 | 0 | 1 | 2 | 14 | 1 | 8 posts and articles, 1 podcast or video | | F2 | 10 | 0 | 2 | 3 | 3 | 23 | 6 | 10 posts and articles, 2 podcasts and video, 1 publication | | F3 | 3 | 6 | 0 | 0 | 0 | 10 | 0 | 5 posts and articles, 1 podcast or video | | F4 | 4 | 2 | 0 | 2 | 5 | 15 | 1 | 7 posts and articles, 2 podcasts and video | | F5 | 8 | 1 | 0 | 0 | 6 | 16 | 3 | 7 posts and articles, 4 podcasts and video | | F6 | 3 | 4 | 0 | 2 | 5 | 16 | 6 | 1 post or article, 5 podcasts and video | ### Trial dimensions - Primary endpoint: Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR): F1 (3 shared claims), F3 (1 shared claims), F4 (1 shared claims) - Primary endpoint: Overall Survival (OS): F1 (3 shared claims), F2 (2 shared claims), F3 (1 shared claims) - Secondary endpoints: F1 (1 shared claims), F2 (3 shared claims), F4 (1 shared claims), F6 (1 shared claims) - Population and setting: F3 (2 shared claims), F4 (2 shared claims) - The comparison: F2 (1 shared claims), F4 (4 shared claims) - Safety and tolerability: F1 (3 shared claims), F2 (15 shared claims), F3 (2 shared claims), F4 (1 shared claims), F6 (1 shared claims) - Design and conduct: F1 (1 shared claims), F4 (7 shared claims), F5 (2 shared claims) ## Abbreviations - ADC: antibody–drug conjugate - BICR: blinded independent central review - HCP: healthcare professional - MCP: Model Context Protocol, how AI agents read the report - NPI: National Provider Identifier, the US registry number for clinicians - OS: overall survival - PFS: progression-free survival - RECIST: Response Evaluation Criteria in Solid Tumors ## Examples from the report Statements as the report records them, by the speaker's role only. Full statements, speaker names and links to each source are in the report. - Medical oncologist, ex-US, identity checked against a staff page · post on LinkedIn · Oct 2026 (finding F1): A medical oncologist considers longer-term safety, biomarker analyses and optimal treatment sequencing essential before widespread adoption of sacituzumab tirumotecan in this setting. ## What's inside | Section | Items | Access | | --- | ---: | --- | | Findings with interpretation, counterviews and limits | 6 | Titles free | | Detailed analysis | 16 sections | Paid | | Verified statements with short source quotes and links | 222 | Paid | | Who said each statement: the cited speakers | 35 | Every edition | | Speakers with a clinical role confirmed by the NPI registry or a staff page | 22 | Every edition | | Speakers with verified IDs as data (NPI, ORCID, staff page) | 26 | Every edition | | CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition | | Trial aspects mapped | 11 | Free | | Sources with links | 72 | Counts free | | MCP access for your AI agent, same license key | Included | Every edition | Every edition, the free report included, names who said each statement, as the source shows them. Each named speaker's card gives a clinical role only when the NPI registry or the person's own institution's staff page confirms it, and says which; a role only a source states is labelled as the source's. Here 22 of the 35 cited speakers have a role confirmed that way. Every edition also comes with MCP access, so your AI agent reads the same evidence with your license key, and with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself. Social accounts are not included. The IDs are for checking attribution inside your organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians. ## Trial aspects 11 discussed · 0 no commentary found · 0 assessment incomplete. | Aspect | Coverage | Statements | Sources | | --- | --- | ---: | ---: | | Primary endpoint: Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR) | discussed | 20 | 18 | | Primary endpoint: Overall Survival (OS) | discussed | 20 | 16 | | Secondary endpoints | discussed | 15 | 13 | | Population and setting | discussed | 25 | 14 | | The comparison (The registered arms and what clinicians said about how they compare.) | discussed | 9 | 7 | | Safety and tolerability | discussed | 30 | 21 | | Design and conduct | discussed | 13 | 8 | | Clinical positioning and strength of endorsement | discussed | 51 | 37 | | Patient selection, subgroup uncertainty and ADC sequencing | discussed | 12 | 9 | | Authorization, funding, access and clinical-trial discussion | discussed | 20 | 12 | | Targeted-delivery rationale and earlier disease-specific sac-TMT evidence | discussed | 25 | 12 | Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply. ## Sources | Channel | Statements | Cited | Screened | | --- | ---: | ---: | ---: | | **Video & audio · 122 statements · 55%** (from 16 videos and episodes · about 8 per source) | | | | | YouTube | 68 | 7 | 7 | | Podcasts | 54 | 9 | 9 | | **Posts · 95 statements · 43%** (from 54 posts · about 2 per source) | | | | | X threads | 67 | 42 | 117 | | LinkedIn posts | 19 | 8 | 10 | | Bluesky threads | 9 | 4 | 17 | | **Primary sources · 5 statements · 2%** (cited for context, not screened · from 2 sources · about 3 per source) | | | | | Publications (primary source, cited for context) | 4 | 1 | not screened | | Registry (primary source, cited for context) | 1 | 1 | not screened | - Screened window: 2024-04-05 to 2026-11-05 - Cited window: 2024-05-01 to 2026-11-05 - Retrieved: 2026-11-12 Statements count each verified statement once, split evenly over the sources it cites. Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context. ## The trial From ClinicalTrials.gov. - Title: A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy (MK-2870-005/ENGOT-en23/GOG-3095) - Also known as: ENGOT-en23, GOG-3095 - Registry: NCT06132958 (https://clinicaltrials.gov/study/NCT06132958) - Study IDs: 2870-005 · 2023-504816-14-00 (EU CT) · U1111-1288-7581 (UTN) · jRCT2031240041 (Japan Registry of Clinical Trials (jRCT)) - Sponsor: Merck Sharp & Dohme LLC - Collaborators: European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation - Design: Phase 3 · interventional, randomized, parallel, phase3 - Status: Active, not recruiting - Enrollment: 710 (estimated) - Start: 2023-12-06 (actual) - Primary completion: 2028-01-10 (estimated) - Primary endpoint: Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR) (Up to approximately 27 months) - Primary endpoint: Overall Survival (OS) (Up to approximately 48 months) - Intervention: Sacituzumab tirumotecan (biological) - Intervention: Doxorubicin (drug) - Intervention: Paclitaxel (drug) - Intervention: Nab-paclitaxel (drug) - Intervention: Rescue medications (drug) ## Scope and limits This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice. - Not yet captured in this edition: a view on treatment history and unmet need when considering antibody–drug conjugates after chemotherapy and immunotherapy; a view on checkpoint switching versus adding lenvatinib after progression on immunotherapy in endometrial cancer; a remark on an inference explicitly qualified as an assumption without supporting data; a view on prioritizing a treatment-comparison trial in previously treated recurrent or advanced endometrial cancer. - Discussion that does not name the trial may be missing from this edition. - 5 matching sources (3 YouTube videos, 2 X threads) could not be read and are not included. - 1 passage in 1 source used in this report was not fully assessed for clinician views, so a view there may be missing from this edition. - 333 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted. - Further source limits: 5 sources about other trials or topics are not included. - The sources reviewed for this edition are not representative of all HCPs or all public discussion, and source totals cannot be interpreted as numbers of independent clinicians. - Two social threads and three video transcripts were unavailable. Other passages could not be described reliably or fully: the origin of reported evidence was unclear in two, while additional material left safety qualifications, prior-treatment distinctions, an account’s prioritization or an explicit evidence limitation incompletely represented. Another passage was not fully assessed. These gaps may obscure minority positions and practical qualifications. - The treatment-choice discussions are not exhaustive. Absence of an option or exception from this report does not show that a speaker rejected it or failed to discuss it. - Several passages cannot be assigned to a named speaker. A guest list, program description, profile or research identity does not establish who spoke those words. - Public accounts, organizations, investor-oriented commentary and an episode containing AI-generated content contribute some views; their inclusion does not establish clinical expertise or independent clinical endorsement. - Earlier design and access discussions, May 2026 announcements and October–November 2026 detailed-result commentary concern different information states. Dates alone do not demonstrate a change of mind. - Interim follow-up, unresolved subgroup and biomarker questions, limited quality-of-life detail and absent comparative sequencing evidence constrain implementation interpretations. - Safety accounts distinguish overall adverse events, treatment-related adverse events, serious events, discontinuation and treatment-related deaths; these measures should not be merged. - No exact sacituzumab tirumotecan label was available, and jurisdictional authorization descriptions conflict, so the report does not determine current approval or reimbursed access. - Small retrospective rechallenge series, individual clinical experiences and subsequent-trial anecdotes do not provide direct comparative evidence against sac-TMT. - Source-described roles and trial involvement are not independently confirmed professional appointments or proof of an external, independent assessment. Professional associations also do not establish current employment. - The ovarian-cancer educational account is development context only. Its activity observations and corrected description of a path to Phase III are not endometrial-cancer TroFuse-005 results. Its full toxicity and supportive-care discussion is not captured here, so the account should not be used as a complete benefit–risk appraisal or evidence of comparative tolerability. How reports are built and checked: https://www.erudio.com/methods ## Editions and corrections - v1.0.0, edition 1, accepted 2026-11-12 UTC: current edition - Routine maintenance: 3 fixes (names, counts, text): - 2026-11-12 UTC: Corrected to match the delivered report: the question clinicians left open; per-finding counts; the limitations; the examples from the report; the abstract, which no longer repeats the open question; the report description. - 2026-11-12 UTC: A sentence that said more than its speaker's words was removed. - 2026-11-12 UTC: The trial's name is spelled as its investigators write it, “TroFuse-005” (NCT06132958), outside quotations (was “Trofuce”). Each new edition gets a new version: a new or changed finding raises the middle number (1.0.0 to 1.1.0), added evidence or newly verified speakers alone the last number (1.0.0 to 1.0.1), and a change of report format the first number. A correction fixes the published edition in place without making a new edition, so the version stays the same. Changes are corrections that add, remove or change a statement or finding, or withdraw a source; routine maintenance (people cards, names and spellings, recounts, tags and page wording) changes none. Every correction is listed here with its date. Last checked for new commentary 2026-11-12 UTC. No changes. ## Offer - Size: Standard · 222 verified statements · 66 from 22 confirmed clinicians - Current edition: $1,250. A purchase starts a check for new commentary and any newer edition follows at no charge - 3 months of updates: $2,200 - 6 months of updates: $3,100 - 12 months of updates: $4,400 - Every product includes verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself (26 identity-verified speakers now); social accounts are not included. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians. - Pricing: https://www.erudio.com/pricing - Buy now (card, through Stripe): https://www.erudio.com/reports/trofuse-005-nct06132958 - Agents: POST https://www.erudio.com/api/orders with {"report": "trofuse-005-nct06132958", "product": "edition" | "updates-3" | "updates-6" | "updates-12", "buyer_email": "...", "licence_key": ""}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again - Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=trofuse-005-nct06132958 ## Cite Erudio Health. TroFuse-005 (NCT06132958): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 12, 2026. https://www.erudio.com/reports/trofuse-005-nct06132958 ## Questions ### How much does the TroFuse-005 report cost? One edition costs $1,250 (Standard · 222 verified statements · 66 from 22 confirmed clinicians). With updates: 3 months $2,200, 6 months $3,100, 12 months $4,400. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current. ### What does the TroFuse-005 report cover? 222 statements from 72 sources (9 podcasts, 7 videos, 54 posts, 1 paper, 1 registry record), 66 of them from 22 confirmed clinicians, each linked to its source. Commentary checked Nov 12, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus. ### Can my AI agent read or buy the TroFuse-005 report? Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "trofuse-005-nct06132958" }) previews it and create_order({ "report": "NCT06132958", "product": "edition", "buyer_email": "" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. [Connect your AI client](https://www.erudio.com/developers/connect) ### How current is the TroFuse-005 report? Edition 1 (version 1.0.0), accepted Nov 12, 2026 UTC; last checked for new commentary Nov 12, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week. ## Machine access - JSON: https://www.erudio.com/reports/trofuse-005-nct06132958.json - Markdown: https://www.erudio.com/reports/trofuse-005-nct06132958.md - Change feed (JSON Feed: new editions and changes): https://www.erudio.com/reports/trofuse-005-nct06132958/feed.json - MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "trofuse-005-nct06132958"}`